KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Return on Sales: 2010-2025

Historic Return on Sales for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to 0.34%.

  • Novavax's Return on Sales rose 66.00% to 0.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.34%, marking a year-over-year increase of 66.00%. This contributed to the annual value of -0.27% for FY2024, which is 28.00% up from last year.
  • Per Novavax's latest filing, its Return on Sales stood at 0.34% for Q3 2025, which was down 18.04% from 0.42% recorded in Q2 2025.
  • Novavax's 5-year Return on Sales high stood at 0.42% for Q2 2025, and its period low was -1.52% during Q4 2021.
  • For the 3-year period, Novavax's Return on Sales averaged around -0.22%, with its median value being -0.32% (2024).
  • Examining YoY changes over the last 5 years, Novavax's Return on Sales showed a top increase of 572bps in 2021 and a maximum decrease of 64bps in 2021.
  • Novavax's Return on Sales (Quarterly) stood at -1.52% in 2021, then skyrocketed by 119bps to -0.33% in 2022, then dropped by 22bps to -0.55% in 2023, then climbed by 28bps to -0.27% in 2024, then skyrocketed by 66bps to 0.34% in 2025.
  • Its last three reported values are 0.34% in Q3 2025, 0.42% for Q2 2025, and 0.38% during Q1 2025.